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0959-8049/ª 2016 Elsevier Ltd. All righAbstract Introduction: Immunological response to human papillomavirus (HPV) in the
development and progression of HPV16þ oropharyngeal squamous cell carcinoma (OPSCC)
(accounting for the majority of viral associated cases) is largely unknown and may provide
important insights for new therapeutic strategies.
Methods: In this prospective clinical trial (UKCRN11945), we examined cell-mediated im-
mune responses to HPV16 E2, E6 and E7 in peripheral blood using IFN-g enzyme-linked
immunosorbent spot assay. CD56þ, CD4þ, CD8þ and regulatory T cell frequencies were also
discerned by flow cytometry. Fifty-one study participants with oropharyngeal carcinoma were
recruited. Control subjects were those undergoing tonsillectomy for benign disease. All pa-
tients were treated with curative intent by radiotherapy  chemotherapy. Disease-specific sur-
vival was investigated by multivariate analysis.
Results: HPV16 DNA was detected in 41/51 of the OPSCC participants. T cell responses against
HPV16E6orE7peptidesweredetected in33/51 evaluablepatients, respectivelyandcorrelatedwith
HPV status. Matched pre- and post-treatment T cell responses were available for 39/51 OPSCC
cases. Within the whole cohort, elevated post-treatment CD8þ response to HPV16 E7 correlated
with longer disease free survival (multivariate DFS p< 0.03). Within the HPVþ OPSCC cohort,





L. Masterson et al. / European Journal of Cancer 67 (2016) 141e151142Conclusions: This is the first study to provide survival data in OPSCC stratified by cell-mediated
immune response to HPV16 peptides. Within the HPV16þOPSCC cohort, enhanced immunore-
activity to antigen E7was linked to improved survival. An increase in regulatory T cell frequencies
after treatment may suggest that immunosuppression can contribute to a reduced HPV-specific
cell-mediated response.
ª 2016 Elsevier Ltd. All rights reserved.1. Introduction
In head and neck squamous cell cancer (HNSCC), im-
munodeficiency has been shown to correlate with a poor
prognosis [1]. However, few studies have addressed the
specific role of cell-mediated immunity in human
papillomavirus (HPV)eassociated OPSCC [2,3]. A
study by de Jong et al. [4] demonstrated that baseline
HPV16 specific CD4þ T cell response in cervical cancer
patients is either absent or severely impaired (despite a
relatively robust immune status). Spanos
et al.[5] recently showed that functional immune
response was critical to achieving adequate tumour
clearance with chemoradiation in a murine model. A
further study revealed that CD8þ T cells reactive to
wild-type p53 are significantly reduced after surgical
excision of HPV16 tumours [6]. Hoffman
et al.[7] investigated CD8þ T cells reactive to HPV16 E7
in a small cohort of patients with OPSCC. As predicted,
these were commonly detected in patients with a positive
HPV16 status but the study lacked survival analysis as a
clinical outcome measure.
Most of the studies above focus on immune response
at the point of diagnosis and before curative therapy. At
present, it is unclear whether conventional treatment
protocols for OPSCC [1] inhibit or promote tumour
immune response mechanisms [8]. Distel et al. [9]
investigated intra-tumoural immune profiles before
and after primary chemoradiation and concluded that
post-therapy cytotoxic T-lymphocyte cells (CTL) were
depleted to a lesser extent than immunosuppressive T
regulatory cells. This is in contrast to the findings of Al-
Taei et al. [10] who found decreased systemic HPV-
specific T cell responses and accumulation of immuno-
suppressive influences in oropharyngeal cancer patients
following radical therapy.
Natural regulatory T cells (Tregs) are important
immunosuppressive cells and have been correlated with
a poor prognosis in HNSCC [1,11]. They have an
important role in homeostasis and can be characterised
by high co-expression of CD4þ and CD25þ [12]. Tregs
inhibit T cell activity by induction of ATP hydrolysis
and apoptosis via the Fas/FasL pathway [13]. An
increasing body of evidence would suggest that they are
responsible for ameliorating tumour-specific immuneresponses [14] and as such are a potential barrier to
immunotherapy [7,15].
In order to understand better the immune profile in
patients with OPSCC, we report the first study to
examine long-term survival outcomes in relation to T-
lymphocyte subsets and specific cell-mediated immune
response to HPV16 E2, E6 and E7.
2. Methods
2.1. Study population
This project received formal approval by the National
Research Ethics Service Committee of East of England
(12/EE/44). Clinical samples were obtained from Cam-
bridge University Hospitals NHS Trust between June
2011 and July 2013.
The study comprised 51 patients with primary
oropharyngeal squamous cell carcinoma and 11 control
subjects with benign disease. Disease stage was classified
using the tumour regional lymph node metastasis
(TNM) classification of malignant tumours [16].
A baseline sample of the tumour was taken for his-
tological analysis and the remainder processed for
DNA  RNA extraction. A consultant histopathologist
with expertise in head and neck pathology reviewed each
tissue block to ensure adequate tumour sampling.
The trial protocol can be downloaded from the
United Kingdom Clinical Research Network (https://
www.ukctg.nihr.ac.uk; study ID 11945). Clinical data
for all subjects are shown in Table 1.
2.2. Lymphocyte cell preparation
A blood sample (40 ml) was drawn at baseline after
diagnosis and 3 months post-treatment. In order to
examine the specificity of the IFN-g enzyme-linked
immunosorbent spot assay (ELISPOT), healthy patients
were recruited to the study, each of whom underwent
tonsillectomy for a benign condition.
Peripheral blood mononuclear cells (PBMCs) were
isolated by density gradient centrifugation using
FicollePaque (GE Healthcare, Sweden) and washed
with phosphate buffered saline (PBS). The extracted
PBMCs were then mixed with foetal calf serum (FCS)
Table 1
Clinical and histopathological data. OPSCC patients had a mean age of 58 years and the male-female ratio was 4:1.






















IVB M Tonsil 61 0 Poor Current þ 16 þ þ þ e CRT þ 43
III M BoT 48 0 Poor Never þ Nil þ e e þ CRT þ 47
IVA M Tonsil 72 1 Mod Former þ 16 e þ þ þ RT e 11 yy
IVA M BoT 59 0 Well Current þ 16 e þ þ e CRT þ 43
IVB F BoT 68 3 n/a Never þ 16 þ þ þ e RT e 14 y
IVA F BoT 49 0 Poor Never þ 16 þ þ þ þ CRT þ 51
IVA M BoT 33 0 Mod Never þ 18 þ þ þ þ CRT e 4
III F Tonsil 67 1 Poor Never þ 16 e þ þ þ RT þ 40
IVA M BoT 57 0 Poor Current þ 16 þ þ þ þ RT e 44
IVA M BoT 65 0 Poor Never þ Nil þ þ þ þ CRT þ 43
IVA F Tonsil 61 0 Mod Current þ 16 þ þ þ e CRT þ 48
I M BoT 77 1 n/a Former þ 16 þ þ þ e RT e 7 y
IVA M Tonsil 51 0 Poor Current þ 16 þ þ þ þ CRT e 12 yy
IVA M Tonsil 49 1 Poor Never þ 16 þ e þ e RT e 4 y
IVA M BoT 57 1 n/a Never þ 16 þ þ þ e CRT e 40
IVA M BoT 64 0 Mod Former þ 16 þ þ þ þ CRT þ 47
IVA M BoT 75 1 Mod Former þ 16 þ þ þ þ RT þ 39
IVA M Tonsil 47 0 Poor Never þ 16 þ þ þ e CRT þ 39
III F Tonsil 60 0 Mod Former þ 16 þ þ þ þ RT e 39
IVA F Tonsil 62 0 Poor Never þ 16 þ þ þ þ RT þ 42
IVA M Tonsil 82 1 Poor Never þ 16 þ þ þ e RT e 4 y
IVA M BoT 52 0 Poor Never þ 16 þ e þ þ CRT þ 43
IVA M Tonsil 58 0 Well Current þ 16 þ þ þ þ CRT þ 30
III M BoT 51 0 Mod Never þ 16 þ þ þ þ CRT e 53
IVA M BoT 40 0 Mod Never þ 16 e e þ þ CRT e 13 yy
IVA M Tonsil 56 2 Poor Never þ 33 þ þ þ þ CRT þ 37
IVA M Tonsil 46 0 Poor Current þ 16 e þ þ þ RT þ 38
III M BoT 53 0 n/a Never e 16 þ þ þ e CRT e 37
IVA M BoT 78 1 Poor Former þ 16 þ e þ e RT þ 37
IVA M Tonsil 58 0 Mod Never þ 16 þ þ þ þ CRT þ 39
IVA M Tonsil 55 0 Mod Current þ Nil þ þ þ þ CRT þ 35
IVA M BoT 81 1 Poor Former þ 16 þ þ þ þ RT e 12 yy
IVA M Tonsil 59 0 n/a Former þ 16 e þ þ e RT þ 36
IVA M Tonsil 61 0 Poor Current þ 16 e e þ þ RT þ 41
IVA F BoT 51 0 Poor n/a þ 16 þ þ þ þ CRT þ 44
III M Tonsil 53 1 n/a Former þ 16 þ þ þ e CRT e 41 # 10 months
III F Tonsil 40 0 Poor Current þ 33 þ þ þ þ RT e 40
I M Tonsil 67 0 n/a Former þ 16 e e þ e RT e 51
IVA M Tonsil 52 0 Poor Current þ 16 þ þ þ þ CRT þ 44
IVA F Tonsil 63 1 Poor Never þ 16 þ þ þ þ CRT þ 44
IVA M BoT 47 0 Poor Never þ 16 þ þ þ þ CRT þ 48
IVA M Soft pal. 61 2 Poor Current e Nil e e e e RT þ 34 # 16 months
IVA F Tonsil 56 0 Mod Current e Nil e e e e CRT þ 48
III M BoT 60 0 Poor n/a e n/a n/a n/a n/a e CRT þ 37






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































L. Masterson et al. / European Journal of Cancer 67 (2016) 141e151144supplemented with 10% dimethyl sulfoxide (Sigma)
before storage in liquid nitrogen.
Pre- and post-therapy samples for each patient were
tested in the same experiment. After thawing and
washing in cold sterile P10 (PBS þ 10% FCS), PBMCs
underwent depletion of CD56þ, CD8þ and CD25þ cells
using magnetic microbeads (Miltenyi Biotec, Surrey,
UK) according to the manufacturer’s instructions. Pu-
rity of the monocyte selection (CD4þ/CD8þ/CD56þ)
was verified by fluorescence-activated cell sorter analysis
(see below). 0.5e1.5  106 CD4þ, CD8þ or CD56þ cells
were each added to a 15-ml conical tube and washed
with culture medium (RPMI 1640 supplemented with
10% FCS, 2-mM glutamine, 100-IU/ml penicillin and
100-mg/ml streptomycin; Gibco, Paisley, UK).
2.3. ELISPOT assays for IFN-g
To measure IFN-g release, flat-bottomed 96-well poly-
vinylidene difluoride membraneebacked plates (Milli-
pore, Bedford, UK) were first washed with sterile PBS
before coating with 50 ml of mouse IgG1 anti-human
IFN-g monoclonal antibody (1-D1K, 15 mg/ml in 0.1M
NaHCO3 buffer; pH 9.5, Mabtech, Sweden) and incu-
bation at 4 C overnight.
The next day, coated wells were washed 6 with PBS
before blocking with 50 ml of culture medium (CM) for
3 h at 37 C. Aliquots of CD4þ/CD8þ/CD56þ cells in
CM (100 mle1  105) were added to each well.
Stimulatory mAbs to CD28 and CD49d (Pharmin-
gen, Oxford, UK) both at 0.5 mg/ml were then added for
CD4þ T cell assays [17]. Only stimulatory mAbs to
CD28 were added for CD8þ T cell assays [18].
To induce non-specific cytokine production (required
for CD4þ or CD8þ cells), 2 ml of phorbol myristate
acetate (5 mg/ml; SigmaeAldrich, UK) and 10 ml of
ionomycin (100 mM concentration; SigmaeAldrich,
UK) were added to each positive control well.
Peptide libraries spanning the entire length of HPV16
E2, E6 and E7 proteins (Mimotopes, Victoria,
Australia) were grouped in pools and added to the
CD4þ/CD8þ cell culture medium to achieve a final
concentration of 1 mM for each peptide, prior to incu-
bation for 18 h at 37 C in 5% CO2.
The cells were then discarded and the plate washed
6 with PBS/0.05% Tween-20. Each well was then
coated with 50 ml (4 mg/ml) of biotinylated anti-human
IFN- antibody (7-B6-1-biotin, Mabtech, Sweden) and
the plates incubated for 2 h at 37 C. A further 6 wash
with PBS/0.05% Tween-20 preceded the addition of a
streptavidinealkaline phosphatase conjugate for 1 h
(prepared according to the manufacturer’s instructions
and added at a volume of 100 ml/well; Biorad, UK). The
reaction was terminated by washing with tap water and
allowed to air-dry. The number of spots in each well was





















































Fig. 1. HPV16 E2, E6 and E7 response detection by IFN-g ELI-
SPOT pre- and post-radical therapy. A response was considered
positive if the average number of spot forming cells (SFCs) in
HPV antigen well was 2 standard deviations (SDs) above the
average of negative control. The frequency of cytokine secreting
CD4þ/CD8þ/CD56þ cells were then derived by the formula:
number of spots/number of cells per well. For this study, we as-
sume that increased staining of CD4þ equates to CD4þ T cells; we
assume that increased staining of CD8þ equates to CD8þ T cells;
we assume that increased staining of CD56þ equates to NK cells.
HPV, human papillomavirus
L. Masterson et al. / European Journal of Cancer 67 (2016) 141e151 1452.4. Flow cytometry
Harvested cells (w1  105) were washed in sterile P10
(PBS þ 10% FCS) and incubated with the relevant
mAbs (each at 25 mg/ml) to surface markers (anti-human
CD4/fluorescein isothiocyanate; anti-human CD8/R-
phycoerythrin-Cy5; anti-human CD56/phycoerythrin;
DAKO, Denmark) for 15 min at 4 C. A further aliquot
of CD4þ cells was separated into CD25neg [negative],
CD25int [intermediate] and CD25high T cells (the latter
two groups representing the Treg population) after
staining with anti-human CD25/phycoerythrin (BD
Biosciences, USA). Purity of the Treg population was
further assessed in a subgroup of patients after staining
for FoxP3. All stained cells were washed again with
sterile P10 before fixation in 1% paraformaldehyde
(Sigma, UK).
2.5. HPV stratification
HPV stratification methods included consensus
p16INK4A IHC, PGMY (L1) PCR; type-specific HPV16
DNA PCR and DNA sequencing in all patients. In some
patients, sufficient quality fresh frozen samples allowed
HPV16 E6/E7 mRNA PCR. In all others HPV DNA in
situ hybridization was performed (Fig. S1). HPV posi-
tive status defined as evidence of HPV16 L1/E6/E7
DNA or HPV16 E6/E7 mRNA  episomal or integra-
tive pattern on HPV DNA ISH  p16INK4A expres-
sion (>70% tumour cell staining).
2.6. Statistical analysis
Statistical calculations were performed using SPSS
version 21 (Chicago, IL, USA). Rates of disease free
survival (DFS) were estimated by means of the
KaplaneMeier method and were compared by the log-
rank test. A two-tailed p value of <0.05 was defined as
significant.
3. Results
3.1. HPV-specific T cell responses correlate with tumour
HPV status
In total, 41/51 of tumour samples were classified as HPV
positive - defined by evidence of HPV16 L1/E6/E7 DNA
or HPV16 E6/E7 mRNA  HPV DNA ISH episomal/
integrative staining pattern. Immunohistochemical
analysis for expression of p16INK4a was demonstrated
for all HPVþ OPSCC samples but also present for 2 out
of 10 OPSCC samples categorised as HPV negative.
When linking HPV16 status with the ELISPOT data,
we found that 80% (33/41) of the patients who had
detectable HPV16 DNA in tumours also had CD4þ or
CD8þ T cell response to HPV16 E6/E7. Only onepatient with a HPV negative tumour displayed such a
response, suggesting a correlation is likely between HPV
positive status of the tumour and T cell response to HPV
antigens. Data summarising HPV status and T cell
response are shown in Fig. S1.
3.2. CD4þ and CD8þ T cell response to HPV16 E7
reduce post-treatment for the majority of patients
Specific IFN-g responses to HPV16 E2, E6 and E7 by
both CD4þ/CD8þ T cells were investigated at initial
diagnosis of malignancy and three months after
completion of chemoradiation for 39/51 patients. Pre-
treatment CD4þ response to E2 was detected for eight
patients (8/30); this frequency decreased slightly after
treatment (8/39). One patient demonstrated a CD8þ
response to E2 prior to treatment only.
Overall, CD8þ T cell responses to HPV16 E6 and E7
peptides were detected pre-treatment in 60% (18/30) and
70% (21/30) of the patients, respectively. Post-treatment
evaluation revealed that there was no significant change
in CD8þ response to E6 (39.5%; 15/38; p < 0.16) and a
significant decreased response to E7 peptide (44.7%; 17/
38; p < 0.02; Fig. 1).
Pre-treatment CD4þ T cell responses to HPV16 E6
and E7 peptides were detected in 60% (18/30) and 70%
(21/30) of the patients, respectively. Post-treatment,
there was a significant decrease in ELISPOT responses
to both E6 (35.9%; 14/39; p < 0.02) and E7 peptides
(43.6%; 17/39; p < 0.01; Fig. 1).
To ascertain sensitivity and specificity of the IFN-g
assay, patients undergoing tonsillectomy for benign
L. Masterson et al. / European Journal of Cancer 67 (2016) 141e151146disease were also subjected to the same analysis at
baseline. All displayed no positive IFN-g response for
either CD4þ or CD8þ T cells except for one subject (1/
11). The same subject displayed evidence for HPV16 L1
DNA on initial HPV stratification.
IFN-g production by CD56 cells (NK cell popula-
tion) was utilised to discern non-specific (innate) im-
mune response within the clinical subgroups. Fig. S2
shows no significant difference was detected for all pa-
tients pre- or post-treatment.
3.3. Decreased CD4:CD8 ratio following radical therapy
The CD4:CD8 ratio pre-treatment was similar to that
seen in healthy controls (3.03 versus 2.87). However,
CD4þ (0.74 versus 0.42  109/L) and CD8þ (0.37 versusFig. 2. Mean haematological parameters (SD) in OPSCC patients b
CD4:CD8 ratio (B) haemoglobin (C) lymphocytes (D) monocytes a
frequencies of CD4þ and CD8þ population. All other subgroups wer0.33  109/L) cell numbers were reduced post-therapy
with a larger proportionate decrease in CD4þ T cells
(p < 0.04; Fig. 2). Haemoglobin level (13.1 versus 12.1 g/
dl), total lymphocytes (1.4 versus 1.1  109/L), mono-
cytes (1.6 versus 1.3  109/L) and platelet count (298
versus 307  109/L), all remained stable before and after
treatment.
3.4. CD4þ/CD25þ T cell frequencies increase in
HPVþ OPSCC patients after treatment
Frequency of CD4þ cells with high co-expression of
CD25þ were examined for the majority of patients [34/
51] using gate-settings as previously described (Fig. 3)
[19,20]. Although the proportion of CD4þ/CD25þ Tregs
did not differ at baseline between the patient groups,efore and after radical therapy. The graph shows changes in (A)
nd (E) platelets. The CD4:CD8 ratios were calculated using the
e taken from the routine full blood count (FBC) in the clinic.
Fig. 3. CD25 expression on CD4þ T cells using flow cytometry.
Flow activated cell sorting (FACS) was undertaken using the
FacsCalibur flow cytometer (BD Biosciences) and analysed with
Flowjo software (Treestar, USA). A) The left panel dotplots
illustrate the expression of CD25 on CD4þ T cells. The right
panels depict histograms used to quantitate CD25 expression:
clear-coloured histograms represent staining with a specific anti-
body to CD25. Grey histograms represent control staining.
Representative patients with high (18.2%) and low (4.2%)
CD25þ expression are illustrated on the top and bottom rows
respectively. B) Frequency distribution (%) of CD4þ/CD25þ for
control, HPV and HPVþ patients before and after treatment.
HPV, human papillomavirus.
L. Masterson et al. / European Journal of Cancer 67 (2016) 141e151 147there was significant elevation in HPVþ OPSCC pa-
tients after treatment (11.6% versus 15.4%; p < 0.02).
FoxP3 expression in the CD4þ/CD25 T cell subsets
revealed the majority of CD4þ/CD25high T cells
expressed FoxP3, whereas CD4þ/CD25neg T cells and
CD4þ/CD25int T cells expressed FoxP3 at very low and
moderate levels, respectively (Fig. S3).
Within a subset of the HPV cohort, a further func-
tional analysis looked at the effect of CD25þ cell
depletion on antigen specific IFN-g responses against
E6/E7 by both the CD4 and CD8 T cell population(Fig. S4). Cytokine response was enhanced significantly
for the post-treatment CD8þ group only (*HPV16 E6
p < 0.03; **HPV16 E7 p < 0.02).3.5. Improved disease free survival with elevated CD8þ T
cell response to HPV16 E7
The average DFS for all patients was 43.7 months (SE
2.5). For the HPV16 þ cohort, the DFS period
increased to 47.3 months (SE 2.3). In those with an
increased CD8þ T cell response to E7, the average DFS
period was 49.6 months ( SE 2.3 Fig. 4 and Fig. S5). A
multivariate proportional hazards model using Cox
regression analysis revealed HPV16 (p < 0.02), retained
or enhanced CD8þ T cell response to E7 (p < 0.03) and
smoking (p < 0.04) to have significant influence on DFS.4. Discussion
Oropharyngeal squamous cell carcinoma is the possible
outcome of infection with high-risk HPV and is pre-
ceded by a phase of persistent HPV infection during
which the host immune system fails to eliminate the
virus. Fortunately, the majority of oral cavity HPV in-
fections are cleared before oncogenic conversion [21].
In this prospective observational study, we report a
systematic analysis of IFN-g response in primary
oropharyngeal carcinoma. The significant finding of this
data set would suggest an attenuated response by CD4þ/
CD8þ T cells to HPV16 peptides after completion of
radical therapy. Specific factors found to influence DFS
include HPV16 status, smoking and post-treatment
CD8þ response to HPV16 E7.
As yet, the majority of HNSCC studies investigating
interaction between T cell response and the HPV16 E6
or E7 oncoproteins are small and confined to a non-
clinical setting [2,3,5,6,10,22,23]. This is in contrast to
the more extensive research evaluating specific immune
response in cervical cancer [4,24e29].
The improved clinical outcome with retained CD8þ
response to HPV16 E7 may contradict data from pre-
vious studies that show a more prominent immunogenic
role for E6 [27]. This situation may have arisen due to
the more preserved status of E7 (compared to E6) in pre-
malignant and malignant disease [28]. E7 has also been
used as the target epitope for many therapeutic vacci-
nation trials for CIN [25,29].
HPV E6 is transcribed off the same transcript as E7
and thus should be expressed in similar frequencies and
quantity. It may be reasonable to assume a similar
antiviral T cell response, particularly for E6*1, which
is the splice isoform of E6 expressed at high levels
(along with E7) in tumours. E7 is expressed at the
expense of full length E6, therefore a spectrum of re-
sponses to E7 and E6*1 and not full length E6 in tu-
mours is possible [26].
Fig. 4. Disease free survival (DFS) stratified by (A) HPV16 status and (B) Post-treatment CD8 response to HPV16 E7. A multivariate
model was developed using Cox regression to investigate the effect of clinical factors on disease free survival (HPV16, DCD4þ T cell
response to E6/E7 [pre-treatment versus post-treatment], DCD8þ T cell response to E6/E7, p16INK4a, Treg frequency (%), T stage, N stage,
sex, physiological performance status, oropharyngeal subsite, histology grade, smoking, concurrent chemotherapy, age and CD8þ/Treg
ratio [pre/post/D ratio]). HPV, human papillomavirus.
Fig. 5. Hypothetical role for PD-1 (programmed death protein 1) in HPV associated OPSCC. PD-1 is an inhibitory receptor expressed on
various immune cells, including activated T cells and Treg cells. By blocking the interaction between PD-1 and its primary ligand, PD-L1
(red circle), T cell effector functions are enhanced by increasing proliferation and cytokine activity (IFN-g). Data from this study would
suggest that further work is required to discern the balance between cytotoxic and regulatory T cells (before and after treatment). HPV,
human papillomavirus.
L. Masterson et al. / European Journal of Cancer 67 (2016) 141e151148CD8þ cytokine response to the HPV16 E7 epitope
was more likely in our HPV16 RNAþ/DNAþ group-
das such it may simply act as a proxy marker for
improved clinical outcome regardless of the immune
phenotype. However, this specific response could haveclinical relevance as CD8þ T cells are the dominant
immune killer cells for virus-infected cells, intracellular
bacteria and cancer cells. Previous studies [23,30] also
indicate that patients with HPV16þ HNSCC exhibit an
increased number of T cells specific for peptides derived
L. Masterson et al. / European Journal of Cancer 67 (2016) 141e151 149from the HPV E7 oncoprotein. Also, HPV-specific T cell
responses [as a marker of HPV infection] would pre-
sumably lead to generalised correlations with improved
survival for most or all CD4þ and CD8þ T cell re-
sponses (E2, E6 and E7).
The reduced T cell responses after treatment noted in
this study cannot be explained by a concurrent decrease
in lymphocytes or memory T cells; absolute numbers
for both groups remained unaffected after radical
therapy (Fig. 3). Instead, there was a significant in-
crease in regulatory T cells noted within the
HPV16þ cohort before and after the treatment (11.6%
versus 15.4%; p < 0.02). These data suggest that
immunosuppression can influence HPV-specific im-
mune response post-treatment; in addition they would
support animal models where an immunodeficient host
failed to clear HPV16 positive tumour cells after
exposure to cisplatin [5].
Whiteside et al. demonstrate a higher Treg frequency
and a lower CD8þ/Treg ratio post chemoradiotherapy
with no stratification by HPV status [31]. The study
authors suggest that the Treg fraction in PBMC is
relatively resistant to chemoradiotherapy, unlike the
CD4þ and CD8þ T cells. This hypothesis was tested
in vitro and demonstrated supportive data. Our study
indicates that increased frequency of Tregs [post-
treatment] is restricted to HPV þ cohort (Fig. 3b). If
confirmed to be the case, important drivers of this
resistance could include pathways related to PDZ-
domain proteins (E6), pRB, p107, p130, wild-type p53
or E7.
Although DFS was not significantly influenced by
Treg frequency before and after treatment, we suggest
further functional studies may be of benefit. In partic-
ular, investigation of PD1 or PDL-1 expression from
tumour infiltrating lymphocytes] pre- or post-treatment
may be of clinical value [32]. A previous study has
demonstrated increased PD1 expression from tumour
infiltrating lymphocytes is linked to improved survival in
HPVþ OPSCC [33]. It may be of interest to determine
whether changes in (or selection for) a PD1-high tumour
cell population drives the balance between cytotoxic and
regulatory T cells (Fig. 5).
Our data reveal two patients assigned to the HPV
OPSCC cohort tested positive for p16INK4A. Potential
reasons for this observation include intra-observer/inter-
observer variation of the immunohistochemical back-
ground stain. In addition, a small but significant cohort
of the false positive HPV samples has p16INK4A mu-
tations that may account for accumulation of inactive
p16INK4A [34]. These data reinforce our previous asser-
tion that p16þ status alone is not a safe or justifiable
method of assigning HPV status to a tumour [1].
Limitations of this research are the small sample size
and the possible insensitivity of the assay due to the
localised nature of the infection. The reduced cohort size
may result in less power to detect associations with E6or E7. Problems with detection of CMI response in
peripheral blood are not surprising since HPV16 is a
specific oropharyngeal subsite infection and conse-
quently the number of circulating memory cells would
be hypothesized to be small. The E2 antigen may also
have a more important role in viral control at an earlier
stage of infection [35]. It would also be of interest to
obtain information regarding sustainability of the IFN-
g ELISPOT response at a more distant time-point after
primary treatment (>5e10 years). We postulate that this
may continue to decrease as antigen exposure becomes
diminished (with clearance of infection or the cancer).
Conversely, a rising CD4þ/CD8þ T cell response may
indicate recurrence of disease.
In summary, we have found that the frequency of
IFN-g secreting CD4þ/CD8þ T cells specific for HPV16
E6 and E7 peptides were decreased in most patients 3
months after radical therapy. Further to this, we observe
a significantly improved DFS outcome in the small
subset of patients who retain or enhance their CD8þ E7
response. HPV16 and smoking status were also found to
correlate with survival. Increased immunosuppressive
influences after treatment (for the HPV16 cohort) are
supported by a concomitant rise in Treg frequencies.
Although the E6 and E7 epitopes are apparently
immunogenic in patients with HPV-associated oropha-
ryngeal carcinoma, it is unclear why specific T cells are
unable to eliminate or prevent oncogenic change at an
earlier stage. Further studies are required to explain this
resistance of tumour targets to cytotoxic T cells and to
find potential strategies that will increase the chances of
developing HPV-based therapeutic vaccine in the future.
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